Abstract
The hypotensive peptide adrenomedullin (AM) is assumed to act as a factor inhibitory on elevation of blood pressure and on progression of the hypertensive organ damage, and plasma AM levels are elevated in patients with hypertension. The aim of the present study is to explore whether or not a rise in plasma AM levels precedes the development of hypertension. Normotensive local residents without apparent cardiovascular or renal disease (n=177) were divided into low and high AM groups based on the median concentration of AM in plasma (11.9 fmol/ml), and followed up for 3 years for development of hypertension. The incidence of hypertension was higher in the residents with high AM than low AM levels (27.8 vs 11.5%, P<0.01), whereas a similar analysis of plasma levels of atrial or brain natriuretic peptides revealed no such difference. The plasma AM level was found to be a significant parameter for the development of hypertension in a univariate analysis (P<0.01), but not in a multivariate analysis. Meanwhile, the plasma AM level was significantly (P<0.01) correlated with age and body mass index (BMI), two variables independently significant for the development of hypertension. The present findings suggest that an elevation of the plasma AM level associated with aging and increased BMI precedes the development of hypertension in the normotensive subjects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commum 1993; 192: 553–560.
Kato J, Tsuruda T, Kitamura K, Eto T . Adrenomedullin: a possible autocrine or paracrine hormone in the cardiac ventricles. Hypertens Res 2003; 26 (Suppl): S113–S119.
Kato J, Tsuruda T, Kita T, Kitamura K, Eto T . Adrenomedullin: a protective factor for blood vessels. Arterioscler Thromb Vasc Biol 2005; 25: 2480–2487.
Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994; 94: 2158–2161.
Kato J, Kobayashi K, Etoh T, Tanaka M, Kitamura K, Imamura T et al. Plasma adrenomedullin concentration in patients with heart failure. J Clin Endocrinol Metab 1996; 81: 180–183.
Suzuki Y, Horio T, Hayashi T, Nonogi H, Kitamura K, Eto T et al. Plasma adrenomedullin concentration is increased in patients with peripheral arterial occlusive disease associated with vascular inflammation. Regul Pept 2004; 118: 99–104.
Shindo T, Kurihara Y, Nishimatsu H, Moriyama N, Kakoki M, Wang Y et al. Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation 2001; 104: 1964–1971.
Shimosawa T, Shibagaki Y, Ishibashi K, Kitamura K, Kangawa K, Kato S et al. Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage. Circulation 2002; 105: 106–111.
Tsuruda T, Kato J, Hatakeyama K, Masuyama H, Cao YN, Imamura T et al. Antifibrotic effect of adrenomedullin on coronary adventitia in angiotensin II-induced hypertensive rats. Cardiovasc Res 2005; 65: 921–929.
Kato J, Eto T . Natriuretic peptides. In: Martini L, ed Encyclopedia of Endocrine Diseases. Academic Press: San Diego, 2004 pp 287–290.
Kato J, Etoh T, Kitamura K, Eto T . Atrial and brain natriuretic peptides as markers of cardiac load and volume retention in primary aldosteronism. Am J Hypertens 2005; 18: 354–357.
Ohta H, Tsuji T, Asai S, Tanizaki S, Sasakura K, Teraoka H et al. A simple immunoradiometric assay for measuring the entire molecules of adrenomedullin in human plasma. Clin Chim Acta 1999; 287: 131–143.
Pousset F, Masson F, Chavirovskaia O, Isnard R, Carayon A, Golmard JL et al. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart J 2000; 21: 1009–1014.
Nagaya N, Nishikimi T, Uematsu M, Yoshitomi Y, Miyao Y, Miyazaki S et al. Plasma adrenomedullin as an indicator of prognosis after acute myocardial infarction. Heart 1999; 81: 483–487.
Kato J, Kitamura K, Uemura T, Kuwasako K, Kita T, Kangawa K et al. Plasma levels of adrenomedullin and atrial and brain natriuretic peptides in the general population: their relations to age and pulse pressure. Hypertens Res 2002; 25: 887–892.
Letizia C, Iacobellis G, Caliumi C, Leonetti F, Cotesta D, Ribaudo MC et al. Acute hyperinsulinemia is associated with increased plasma adrenomedullin concentrations in uncomplicated obesity. Exp Clin Endocrinol Diabetes 2005; 113: 171–175.
Nambu T, Arai H, Komatsu Y, Yasoda A, Moriyama K, Kanamoto N et al. Expression of the adrenomedullin gene in adipose tissue. Regul Pept 2005; 132: 17–22.
Li Y, Totsune K, Takeda K, Furuyama K, Shibahara S, Takahashi K . Differential expression of adrenomedullin and resistin in 3T3-L1 adipocytes treated with tumor necrosis factor-α. Eur J Endocrinol 2003; 149: 231–238.
Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004; 43: 1590–1595.
Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005; 112: 2163–2168.
Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509–516.
Arakawa N, Nakamura M, Aoki H, Hiramori K . Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol 1996; 27: 1656–1661.
Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655–663.
Acknowledgements
The present study was partly supported by Grants-in-aid for Scientific Research and for the 21st Century COE Program (Life Science) from MEXT, Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kato, J., Kitamura, K. & Eto, T. Plasma adrenomedullin level and development of hypertension. J Hum Hypertens 20, 566–570 (2006). https://doi.org/10.1038/sj.jhh.1002033
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1002033
Keywords
This article is cited by
-
The effects of antihypertensive medications on severity and outcomes of hypertensive patients with COVID-19
Journal of Human Hypertension (2022)
-
Association between MR-proADM concentration and treatment intensity of antihypertensive agents in chronic kidney disease patients with insufficient blood pressure control
Scientific Reports (2021)
-
Pathophysiological functions of adrenomedullin and natriuretic peptides in patients with primary aldosteronism
Endocrine (2015)
-
Do increased plasma adrenomedullin levels in normotensive subjects precede hypertension?
Journal of Human Hypertension (2006)